Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026
October 24, 2026
October 24, 2026
BOSTON, Massachusetts, Oct. 24 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026
*
Results suggest that introducing tarlatamab, a bispecific T-cell engager, earlier in treatment could meaningfully extend survival for a broader group of p . . .
* * *
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026
*
Results suggest that introducing tarlatamab, a bispecific T-cell engager, earlier in treatment could meaningfully extend survival for a broader group of p . . .